Dear Dynamic Wealth Report Reader,
As many of you know, we're in the business of making money for our subscribers. You may not realize it, but we only do well when you do well.
And that's why I'd like you to sign up ASAP for our Biotech Supertrader newsletter.
You see, biotech stocks are skyrocketing right now. The entire sector is up nearly 30% on the year:
And individual names are doing even better...
For example, we closed one of the stocks in our portfolio, Synta Pharmaceuticals (SNTA), for an 83% gain this year.
On another pick we made, Amarin Corp (AMRN), we captured a 79% gain in just a few months.
Now it's too late to buy these 2 names, they've already had a huge run. But our Biotech Supertrader service is CHOCK FULL of similar biotech companies that could see the same gains. Plus we've got some new recommendations coming out very soon that you'll want to buy for your own portfolio.
So please, take a moment to see what Biotech Supertrader is all about. I'd hate for you to miss out on the tremendous rally that's going on in this sector right now!
Click here for details...
Sincerely,
John Alexander, Editor
Dynamic Wealth Report
P.S. In response to our customer requests, we now offer a very affordable quarterly option on all of our research services-- including Biotech Supertrader. So now you can experience the profit-pulling power of biotech stocks, without being locked into a one year subscription! Click here for details... | | | | | | Copyright 2012 Hyperion Financial Group, LLC. All Rights Reserved. Protected by copyright laws of the United States and international treaties. This email may only be used pursuant to the subscription agreement controlling use of the Dynamic Wealth Report website and any reproduction, copying, or redistribution of this email or its contents, in whole or in part, is strictly prohibited without the express written permission of Hyperion Financial Group, LLC.
LEGAL DISCLAIMER: Neither Hyperion Financial Group LLC nor any of it's employees, contractors or officers are registered investment advisors or a Broker/Dealer. As such, Hyperion Financial Group, LLC does not offer or provide personalized investment advice. Although Hyperion Financial Group, LLC employees and contractors may answer general customer service questions, they are not licensed under securities laws to address your particular investment situation. Nothing in this report, nor any communication by our employees or contractors to you should be considered personalized investment advice.
Owners and writers may have positions in the securities that are discussed. However, no associated employees or contractors may intentionally engage in any transaction that directly or indirectly competes with the interests of our subscribers. We accept no compensation from any companies mentioned in our reports.
Past performance is no guarantee of future results. All information is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor is it to be construed as a recommendation to buy, hold or sell any security. All opinions, analyses and information contained herein are based on sources believed to be reliable and written in good faith, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. Investments recommended in this publication should only be made after consulting with your financial advisor. | |
No comments:
Post a Comment
Keep a civil tongue.